AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$FTRE

Morais Mark A. sold $89K of FTRE

Morais Mark A. (Chief Operating Officer) sold 4,892 shares of Fortrea Holdings Inc. (FTRE) at $18.19 on 2026-08-19.

Original reporting
SEC EDGAR · Morais Mark A.
Published Aug 19, 2026, 10:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 10:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FTRE
Neutral
high confidence
Mentioned
$FTRE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The disclosed sale is modest and does not provide a clear trading signal.

02

Market read

Limited relevance; the insider sale is small and unlikely to affect market perception.

03

What to watch

The sale was not pre‑arranged; however, the officer retains a sizable position.

Relevance 3/10Novelty 4/10Timing: reported today

Background

Form 4 filings disclose insider transactions; traders monitor them for potential signals.

Company-level read

Ticker impact

$FTRENeutralHigh confidence
Context

COO Mark A. Morais sold 4,892 shares for $88,985, reducing his stake to 77,786 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size is small relative to market cap and no 10b5-1 plan was used.

Market effects

Sector

None; the sale does not affect the broader sector.

Regional

None; limited to Fortrea shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns, but no pattern suggests material risk.

Key entities

  • Company
    Fortrea Holdings Inc.

    US‑listed specialty chemicals producer.

  • Insider
    Mark A. Morais

    Chief Operating Officer of Fortrea.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FTRE insider trading history →

Related articles

SEP 2
$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

finanznachrichten.de2 min
JUL 30
$FTREHighAI 9/10

Fortrea Q2 Earnings Call Highlights

"The environment has become more supportive, but our results are not simply the result of market recovery," Thakral said, attributing the performance to changes in commercial execution, including improved global coordination, a sharper focus on opportunities where the company can compete effectively and a clearer approach to serving distinct customer segments. Thakral said Fortrea's clinical pharmacology services business was a particular area of strength.

yahoo.com6 min
JUL 29
$FTREMedAI 8/10

Fortrea (NASDAQ:FTRE) Reports Strong Q2 CY2026, Full

Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 revenue of $678.2 million, down 4.5% year over year but 4.7% above market expectations, according to the company. Full-year revenue guidance was $2.66 billion at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was $0.23, 27.2% above consensus.

financialcontent.com4 min
JUL 29
$FTREMed

Fortrea Holdings Inc. (FTRE): Results of Operations and Financial Condition

Fortrea Holdings Inc. (FTRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fortrea Reports Second Quarter 2026 Results Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: • Revenues of $678.2 million • Book-to-bill

SEC EDGAR 8-K4 min